Ivanova A M, Imomalieva K M, Narovlyansky A N, Izmest'eva A V, Sarymsakov A A, Bilalov E N, Ershov F I
National Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya, Moscow, 123098, Russia.
Tashkent Medical Academy, Tashkent, 100109, Uzbekistan.
Vopr Virusol. 2019;64(5):238-245. doi: 10.36233/0507-4088-2019-64-5-238-245.
The complexity of the treatment of herpetic keratoconjunctivitis is due to the severity of the disease, complications, the transition to chronic relapsing forms and the insufficient effectiveness of the drugs used, which leads to a steady increase in the number of patients. The aim of the study was to evaluate the therapeutic efficacy of the eye drug films «GlazAvir» in the experimental model of acute herpetic eye infection in rabbits.
to study the specific activity of «GlazAvir» and compare the long-term indicators of the level of manifestation of individual clinical signs of keratoconjunctivitis.
In the work we used rabbits of the Chinchilla breed, the herpes simplex virus type 1 and the eye drug films «GlazAvir». A model of ophthalmic herpetic infection was formed by infection of rabbits with virus-containing material of a pre-scarified eye cornea against the background of local anesthesia. Аnimals were treated with the drug «GlazAvir» - 1 application per day for 7 days. Animals were observed daily for 15 days, then every 3 days until the 25th day of observation. The effectiveness of the drug was evaluated at the peak of the development of the pathological process.
There was a decrease in mortality from 50 to 20%, and an increase in average life expectancy by 27.87%, compared with the control in animals treated with «GlazAvir». It was noted after activation of herpetic keratoconjunctivitis on the 2nd - 5th day, at the peak of the disease (6-9th day) a statistically significant decrease in the activity of the pathological process (p<0.05) by rabbits treated with the «GlazAvir» ophthalmic drug films. The tendency to normalization by the rabbits treated with the «GlazAvir» preparation was observed until the 14th day.
The data obtained indicate the pronounced effectiveness of the «GlazAvir» preparation in the treatment of experimental herpesvirus keratoconjunctivitis.
疱疹性角膜结膜炎治疗的复杂性源于疾病的严重性、并发症、向慢性复发形式的转变以及所用药物疗效不足，这导致患者数量持续增加。本研究的目的是评估眼药膜“GlazAvir”在兔急性疱疹性眼部感染实验模型中的治疗效果。
研究“GlazAvir”的特异性活性，并比较角膜结膜炎个体临床症状表现水平的长期指标。
本研究使用了青紫蓝兔品种、1型单纯疱疹病毒和眼药膜“GlazAvir”。在局部麻醉的背景下，用预先划痕的眼角膜含病毒材料感染兔子，建立眼部疱疹感染模型。动物每天使用一次“GlazAvir”药物，持续7天。每天观察动物15天，然后每3天观察一次，直至观察的第25天。在病理过程发展的高峰期评估药物的有效性。
与对照组相比，用“GlazAvir”治疗的动物死亡率从50%降至20%，平均预期寿命增加27.87%。在第2 - 5天疱疹性角膜结膜炎激活后，即在疾病高峰期（第6 - 9天），用“GlazAvir”眼药膜治疗的兔子病理过程的活性有统计学意义的降低（p<0.05）。在用“GlazAvir”制剂治疗的兔子中，直到第14天都观察到有恢复正常的趋势。
所获得的数据表明“GlazAvir”制剂在治疗实验性疱疹病毒性角膜结膜炎方面具有显著疗效。
